Engineers Gate Manager LP Purchases 282,818 Shares of CVS Health Corporation $CVS

Engineers Gate Manager LP lifted its position in CVS Health Corporation (NYSE:CVS) by 96.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 576,203 shares of the pharmacy operator’s stock after buying an additional 282,818 shares during the period. Engineers Gate Manager LP’s holdings in CVS Health were worth $45,727,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Caitong International Asset Management Co. Ltd increased its position in shares of CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after buying an additional 281 shares in the last quarter. Swiss RE Ltd. bought a new stake in shares of CVS Health in the 4th quarter valued at $26,000. Ares Financial Consulting LLC bought a new stake in shares of CVS Health in the 4th quarter valued at $29,000. Dogwood Wealth Management LLC increased its position in shares of CVS Health by 93.7% during the fourth quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator’s stock worth $29,000 after acquiring an additional 179 shares in the last quarter. Finally, GoalVest Advisory LLC acquired a new stake in shares of CVS Health during the fourth quarter worth $32,000. Institutional investors own 80.66% of the company’s stock.

CVS Health Stock Performance

Shares of CVS opened at $99.06 on Thursday. CVS Health Corporation has a 12 month low of $58.50 and a 12 month high of $102.77. The firm has a fifty day simple moving average of $88.51 and a 200 day simple moving average of $81.24. The stock has a market capitalization of $126.40 billion, a price-to-earnings ratio of 43.64, a PEG ratio of 0.99 and a beta of 0.62. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. During the same quarter in the prior year, the company posted $2.25 earnings per share. The firm’s revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Research analysts forecast that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. JPMorgan Chase & Co. increased their target price on CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Argus increased their target price on CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a report on Thursday, May 14th. Mizuho increased their target price on CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Monday, June 8th. TD Cowen increased their target price on CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Finally, Barclays increased their target price on CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a report on Tuesday, May 26th. Twenty-two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and an average price target of $100.68.

Insider Buying and Selling

In other news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the sale, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This represents a 87.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the sale, the director owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 3,441,551 shares of company stock worth $323,703,977. Company insiders own 0.85% of the company’s stock.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.